Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J, Bendstrup E, Crestani B, Günther A, Olschewski H, Sköld CM, Wells A, Wuyts W, Koschel D, Kreuter M, Wallaert B, Lin CY, Beck J, Albera C. Behr J, et al. Among authors: wuyts w. Lancet Respir Med. 2016 Jun;4(6):445-53. doi: 10.1016/S2213-2600(16)30044-3. Epub 2016 May 5. Lancet Respir Med. 2016. PMID: 27161257 Clinical Trial.
Medical Therapy in Idiopathic Pulmonary Fibrosis.
Antoniou KM, Wuyts W, Wijsenbeek M, Wells AU. Antoniou KM, et al. Among authors: wuyts w. Semin Respir Crit Care Med. 2016 Jun;37(3):368-77. doi: 10.1055/s-0036-1582010. Epub 2016 May 27. Semin Respir Crit Care Med. 2016. PMID: 27231861 Review.
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, Wells AU, Whelan TP, Wuyts W, Moreau E, Patterson SD, Smith V, Bayly S, Chien JW, Gong Q, Zhang JJ, O'Riordan TG. Raghu G, et al. Among authors: wuyts w. Lancet Respir Med. 2017 Jan;5(1):22-32. doi: 10.1016/S2213-2600(16)30421-0. Epub 2016 Dec 7. Lancet Respir Med. 2017. PMID: 27939076 Clinical Trial.
Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
Behr J, Nathan SD, Harari S, Wuyts W, Kirchgaessler KU, Bengus M, Gilberg F, Wells AU. Behr J, et al. Among authors: wuyts w. Respir Med. 2018 May;138:13-20. doi: 10.1016/j.rmed.2018.03.019. Epub 2018 Mar 16. Respir Med. 2018. PMID: 29724385 Free article.
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG; INMARK trial investigators. Maher TM, et al. Lancet Respir Med. 2019 Sep;7(9):771-779. doi: 10.1016/S2213-2600(19)30255-3. Epub 2019 Jul 17. Lancet Respir Med. 2019. PMID: 31326319 Free article. Clinical Trial.
365 results